Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.68 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 5/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TERT | O14746 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL616732 | 1.00 | PRCP (0.68) | PRCPDPP7TLR2HTR2CHTR2B | |
| SCHEMBL496387 | 1.00 | PRCP (0.68) | PRCPDPP7TLR2HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL4320225 | 0.98 | PRCP (0.66) | PRCPDPP7TLR2HTR2CHTR2B | |
| Acetic Acid SCHEMBL2183483 | 0.94 | PRCP (0.62) | PRCPDPP7TLR2HTR2CHTR2B | |
| SCHEMBL13990631 | 0.94 | PRCP (0.61) | PRCPDPP7TLR2HTR2CHTR2B | |
| SCHEMBL13359247 | 0.94 | PRCP (0.61) | PRCPDPP7TLR2HTR2CHTR2B | |
| SCHEMBL4710537 | 0.94 | PRCP (0.61) | PRCPDPP7TLR2HTR2CHTR2B | |
| SCHEMBL22019454 | 0.90 | PRCP (0.57) | PRCPDPP7TLR2HTR2CHTR2B | |
| SCHEMBL23169303 | 0.90 | — | — | |
| Trifluoroacetic Acid SCHEMBL3332141 | 0.88 | PRCP (0.56) | PRCPDPP7TLR2HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108660131-B | Preparation method of immobilized nitrile hydratase and (S) -N-ethylpyrrolidine-2-formamide | 浙江工业大学 | 2020-07-21 | — | — | CN | claimed |
| CN-108660131-A | The preparation method of immobilization hydrating nitrile group enzyme and (S)-N- ethyl pyrrolidine -2- formamides | 浙江工业大学 | 2018-10-16 | — | — | CN | claimed |
| EP-1255752-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2002-11-13 | — | — | EP | claimed |
| WO-2001060814-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-08-23 | — | — | WO | claimed |
| US-5140009-A | Stable against proteolytic enzymes; anticarcinogenic agents; urogenital disorders | TAP PHARMACEUTICALS, INC. (US) | 1992-08-18 | — | — | US | claimed |
| CN-115703765-B | Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-11691995-B2 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| CN-115703765-A | Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2023-02-17 | — | — | CN | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| CN-108660131-B | Preparation method of immobilized nitrile hydratase and (S) -N-ethylpyrrolidine-2-formamide | 浙江工业大学 | 2020-07-21 | — | — | CN | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| EP-0144230-B1 | GROWTH PROMOTANTS FOR ANIMALS | Pfizer Limited (GB) | 1990-08-08 | — | — | EP | disclosed |
| US-4758552-A | Gonadoliberin derivatives containing an aromatic aminocarboxylic acid in the 6-position, pharmaceutical and veterinary compositions containing them and process for preparing same | INNOFINANCE ALTALANOS INNOVACIOS PENZINTEZET (HU) | 1988-07-19 | — | — | US | disclosed |
| US-4647553-A | Gonadoliberin derivatives and process for the preparation thereof | INNOVACIOS ALAP KOZPONTI VALTO ES HITELBANK RT. (HU) | 1987-03-03 | — | — | US | disclosed |
| US-4562197-A | CATTLE, POULTRY | PFIZER INC. (US) | 1985-12-31 | — | — | US | disclosed |
| US-4554100-A | ENZYME INHIBITORS | SPOFA, SPOJENE PODNIKY PRO ZDRAVOTNICKOU VYROBU (CS) | 1985-11-19 | — | — | US | disclosed |
| EP-0049628-B1 | NONAPEPTIDE AND DECAPEPTIDE ANALOGS OF LHRH, USEFUL AS LHRH ANTAGONISTS, METHODS OF MAKING THEM, AND THEIR PHARMACEUTICAL USES | SYNTEX (U.S.A.) INC. (US) | 1985-07-03 | — | — | EP | disclosed |
| EP-0144230-A2 | Growth promotants for animals | Pfizer Limited (GB) | 1985-06-12 | — | — | EP | disclosed |
| EP-0130409-A2 | Slow-release composite and process for producing the same | Takeda Chemical Industries, Ltd. (JP) | 1985-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691995-B2 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications | NOS2, NOS3, NOS1 | PRCP 895/4885DPP7 1122/4885TLR2 2611/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | PRCP 3133/4885DPP7 4011/4885TLR2 4802/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | PRCP 3293/4885DPP7 4067/4885TLR2 4763/4885 |
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | PRCP 3073/4885DPP7 3960/4885TLR2 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.